CytomX Therapeutics, Inc. Restructuring Charges
CytomX Therapeutics, Inc. (CTMX) reported Restructuring Charges of $7.15 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2022-11-08
- CytomX Therapeutics, Inc. restructuring charges for the quarter ending 2022-09-30 was $7.15M.
| Period end | Restructuring Charges 3 month |
|---|---|
| 2022-09-30 | $7.15M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |